US FDA Grants Qualified Infectious Disease Product Designation to Venus Remedies’ VRP-034, a Novel Polymyxin B Formulation

▴ Venus Remedies
The QIDP designation by the United States Food and Drug Administration (US FDA) underscores the urgent global need for safer polymyxin-based therapies

  • VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate, uniquely developed to mitigate the nephrotoxic effects associated with conventional polymyxin B (PMB) therapy
  • Key preclinical findings for VRP-034 included up to 70% reduction in nephrotoxicity compared to marketed PMB

 

India, April 17, 2025-- Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading pharmaceutical company specializing in critical care injectables, today announced that its investigational product VRP-034 has been granted Qualified Infectious Disease Product (QIDP) designation by the United States Food and Drug Administration (US FDA) for the treatment of bloodstream infections caused by polymyxin B (PMB)-susceptible strains in adults.

Developed by Venus Medicine Research Centre (VMRC), the R&D division of Venus Remedies, VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate, uniquely developed to address the nephrotoxic effects associated with conventional polymyxin B therapy.

The QIDP designation, granted under the Generating Antibiotic Incentives Now (GAIN) Act, provides VRP-034 with significant regulatory benefits, including priority review, eligibility for fast track designation, and an additional five years of market exclusivity upon approval in the United States.

“Receiving QIDP designation for VRP-034 is a pivotal milestone in our efforts to combat antimicrobial resistance,” said Saransh Chaudhary, CEO, Venus Medicine Research Centre. “QIDP recognition for VRP-034 underscores the urgent global need for safer polymyxin-based therapies and validates the strength of our scientific approach.”

Venus Remedies’ has developed the novel polymyxin-B formulation, VRP-034, using its proprietary Renal Guard technology. The company utilized kidney-on-a-chip technology (based on Organ-on-a-Chip model) to study established kidney injury biomarkers, including KIM-1, cystatin C, NAG, and NGAL, in response to polymyxin-B, an antibiotic used against multidrug-resistant Gram-negative bacteria. These insights directly contributed to the refining of its Renal Guard technology, forming the foundation of the novel formulation, VRP-034, designed specifically to minimize nephrotoxicity while preserving therapeutic efficacy.

Polymyxins, particularly PMB and colistin, are among the last-resort antibiotics used against Multidrug resistance (MDR) infections. However, their clinical use is severely limited by nephrotoxicity, which affects up to 60% of patients. VRP-034 offers a novel solution by preserving the pharmacokinetics and pharmacodynamics of PMB while significantly reducing oxidative stress and renal cell injury, as demonstrated in multiple in vitro and in vivo studies.

Key preclinical findings for VRP-034 include:

  • Up to 70% reduction in nephrotoxicity compared to marketed PMB
  • Robust efficacy against resistant pathogens in both in vitro and animal models
  • Favorable safety profile across multiple toxicity studies using advanced renal biomarkers and human organ-on-a-chip models

This recognition by the US FDA strengthens Venus Remedies’ commitment to innovation in the fight against AMR and underlines the company’s dedication to addressing unmet needs in infectious disease therapy.

 

About Venus Remedies Ltd (venusremedies.com)

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 90+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. The company holds the GMP approvals from European- GMP (INFARMED), PIC/S (Malaysia & Ukraine), SAHPRA, UNICEF, TGA, INVIMA & WHO-GMP, alongside key ISO certifications for quality, environmental, and occupational health and safety management.

Central to its mission, Venus Remedies is a frontrunner in combating antimicrobial resistance (AMR) through its dedicated research division, Venus Medicine Research Centre (VMRC). The company is pivotal in developing advanced antibiotics and β-lactam/β-lactamase inhibitor combinations aimed at tackling multidrug-resistant pathogens. Its notable initiatives like GASAR provide essential data on antibiotic resistance, while the PLEA Trust fosters antibiotic stewardship. As an influential member of the AMR Industry Alliance, India AMR Innovation Hub, and Vivli AMR Registry, Venus Remedies shapes global AMR research and policy. Through strategic collaborations with academic and health organizations worldwide, the company enhances AMR surveillance and supports innovative drug development, affirming its leadership in global healthcare.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Smart Operating Rooms: The Future of Hospital OTNovember 21, 2026
Smartphone Diagnostics: Phones as Medical Screening ToolsNovember 21, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026